Is addiction an illness—can it be treated?

Substance Abuse

Volumn 23, Issue , 2002, Pages 67-94

  McLellan, A Thomas ^a  

^a TREATMENT RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADDICTION; ALCOHOLISM; COMORBIDITY; COST BENEFIT ANALYSIS; CULTURAL ANTHROPOLOGY; ECONOMICS; FEMALE; HEALTH CARE COST; HEALTH PERSONNEL ATTITUDE; HUMAN; LIFESTYLE; MASS SCREENING; MENTAL DISEASE; MOTIVATION; NEWBORN; OPIATE ADDICTION; PATIENT COMPLIANCE; PREGNANCY; PSYCHOLOGICAL ASPECT; PUBLIC OPINION; REVIEW; RISK FACTOR; SOCIAL BEHAVIOR; STATISTICS; TREATMENT OUTCOME; UNITED STATES;

ALCOHOLISM; ATTITUDE OF HEALTH PERSONNEL; COMORBIDITY; COST-BENEFIT ANALYSIS; CULTURE; FEMALE; HEALTH CARE COSTS; HUMANS; INFANT, NEWBORN; LIFE STYLE; MASS SCREENING; MENTAL DISORDERS; MOTIVATION; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; PREGNANCY; PUBLIC OPINION; RISK FACTORS; SOCIAL RESPONSIBILITY; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; UNITED STATES;

EID: 9144254985     PISSN: 08897077     EISSN: 15470164     Source Type: Journal    
DOI: 10.1080/08897070209511508     Document Type: Article

References (198)

1. National Institute on Drug Abuse. See How Drug Abuse Takes the Profit Out of Business. Washington, DC: Government Printing Office; 1991.
2. Merrill J. The Cost of Substance Abuse to America's Health Care System, Report 1: Medicaid Hospital Costs. New York: Columbia University Center on Addiction and Substance Abuse; 1993.
3. Rice DP, Kelman S, Miller LS. Estimates of the economic costs of alcohol, drug.abuse and mental illness, 1985 and 1988. Public Health Rep. 1991;106(3):281-292.
4. Horgan C. Chartbook of Social Indicators for Substance Abuse. Princeton, NJ: Robert Wood Johnson Foundation; 1994.
5. Edelman M. Children's Defense Fund Report. Washington, DC: Children's Defense Fund Press; 2001.
6. Saxe L, Dougherty D, Esty K, Fine M. The Effectiveness and Costs of Alcoholism Treatment Health Technology. Case Study Washington, DC: Office of Technology Assessment; 1983
7. Wall Street Journal. Editorial commentary. July 18, 1997; A12.
8. Fleming MF, Barry KL. The effectiveness of alcoholism screening in an ambulatory care setting. J Stud Alcohol. 1991; 52:33-36.
9. Schuckit, MA. Why don't we diagnose alcoholism in our patients? J Fam Pract. 1987; 25:225-226.
10. Weisner CM, Schmidt L. Alcohol and drug problems among diverse health and social service populations. Am J Public Health. 1993;83:824-829.
11. Conrad P, Schneider JW. Deviance and Medicalization: From Badness to Sickness. Toronto: CV Mosby; 1980.
12. New York Times. Editorial. November 20, 1997;A31.
13. Edwards G, Gross M. Alcohol dependence: provisional description of a clinical syndrome. Br Med J. 1976;1:1058-1061.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders— Fourth Edition. Washington, DC: APA Press; 1995.
15. Aceto MD, Scates SM, Lowe JA, Martin BR. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther. 1996;278:1290-1295.
16. Tsou DT, Patrick SL, Walder JM. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 1995;280:R13- R15.
17. Hasin D, Grant BF, Cottier L, Blaine J, Towle L, Ustun B, Sartorius, N. Nosologjcal comparisons of alcohol and drug diagnoses: a multisite, multi-instrument international study. Drug Alcohol Depend 1997;47:217-226.
18. Rounsaville BJ, Kosten TR, Weissman MM, Prusoff B, Pauls D, Anton SF, Merikangas K. psychiatric disorders in relatives of probands with opiate addiction. Arch Gen Psychiatry. 1991;48(1):33-42.
19. Rounsaville BJ, Babor TF, Meyer RE. Psychiatric symptomatology in alcoholics. Arch Gen Psychiatry. 1989;46:45-51.
20. Smith TW, Turner CW, Ford MH, Hunt SC, Barlow GK, Stults BM, Williams RR. Blood pressure reactivity in adult male twins. Health Psychol. 1987;6(3):209-220.
21. Fagard R, Brguljan J, Staessen J, Thijs L, Derom C, Thomis M, Vlietinck R. Heritability of conventional and ambulatory blood pressures. A study in twins. Hypertension. 1995;26 (6, pt 1):919-924.
22. Hong Y, de Faire U, Heller DA, McClearn GE, Pedersen N. Genetic and environmental influences on blood pressure in elderly twins. Hypertension. 1994;24(6):663-670.
23. Kyvik KO, Green A, Beck-Nielsen H. Concordance rates of insulin dependent diabetes mellitus: a population-based study of young Danish twins. BMJ. 1995;311:913-917.
24. Kaprio J, Tuomilehto J, Koskenvuo M, Romanov K, Reunanen A, Eriksson J, Stengard J, Kesaniemi YA. Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia. 1992;35 (11):1060-1067.
25. Duffy DL, Martin NG, Battistutta D, Hopper JL, Mathews JD. Genetics of asthma and hay fever In Australian twins. Am Rev RespirDis. 1990;142(6, pt 1):1351-1358.
26. Nieminen MM, Kaprio J, Koskenvuo M. A population-based study of bronchial asthma in adult twin pairs. Chest. 1991;100(1):70-75.
27. Johnson EO, van den Bree M, Uhl GR, Pickens RW. Indicators of genetic and environmental influences in drug abusing individuals. Drug Alcohol Depend. 1996; 41 17-23.
28. Pickens RW, Elmer GI, LaBuda MC, Uhl GR. Genetic Vulnerability to Substance Abuse. Berlin, Germany: Springer-Verlag; 1996.
29. Tsuang MT, Lyons MJ, Eisen S, Goldberg J, True W, Lin N, Meyer JM, Toomey R, Faraone SV, Eaves L. Genetic influences on DSM-III-R drug abuse and dependence: a study of 3, 372 twin pairs. Am J Med Genet. 1996;67:473-477.
30. Gynther LM, Carey G, Gottesman I, Vogler GP. A twin study of non-alcohol substance abuse. Psychiatry Res. 1995; 56 (3):213-220.
31. Kendler KS, Heath AC, Neale MC, Kessler RC, Eaves LJ. A population-based twin study of alcoholism in women. JAMA 1992;268:1877-1882.
32. Mitchell BD, Kammerer CM, Blangero J, Mahaney MC, Rainwater DL, Dyke B, Hixson JE, Henkel RD, Sharp RM, Comuzzie AG, VandeBerg JL, Stern MP, MacCluer JW. Genetic and environmental contributions to cardiovascular risk factors in Mexican Americans. The San Antonio Family Heart Study. Circulation 1996;94(9):2159-2170.
33. Svetkey LP, McKeown SP, Wilson AF. Heritability of salt sensitivity in black Americans. Hypertension. 1996;28(5):854-858.
34. Schuckit MA. Subjective responses to alcohol in sons of alcoholics and control subjects. Arch Gen Psychiatry. 1984; 41:879-884.
35. Schuckit MA, Smith TL. An 8-year follow-up of 450 sons of alcoholics and controls. Arch Gen Psychiatry. 1996;53:202-210.
36. Thomasson HR, Edenberg HJ, Crabb DW, Mai XL, Jerome RE, Li TK, Wang SP, Lin YT, Lu RB, Yin SJ. Alcohol and aldehyde dehydrogenase genotypes and alcholism in Chinese men. Am J Hum Genet. 1991;48:667-681.
37. Helzer JE, Canino GJ, Yeh EK, Bland RC, Lee CK, Hwu HG, Newman, S. Alcoholism— North America and Asia. Arch Gen Psychiatry. 1990;47:313-319.
38. Chao YC, Kiou SR, Chung YY, Tang HS, Hsu CS, Li TK, Tin, SJ. Polymorphism of alcohol and aldehyde dehydrogenase genes and alcoholic cirrhosis in Chinese patients. Hepatology. 1994;19:360-366.
39. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science. 1998;242:715-723.
40. Science. October 3, 1997;278(5335):45-69.
41. Special Issue on Addiction. Lancet. 1996;347(9013):1604-1679.
42. Institute of Medicine. Dispelling the Myths About Addiction Washington, DC: National Academy Press; 1995.
43. Institute of Medicine. Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Fulco CE, Liverman CT, Earley LE, eds. Washington, DC: National Academy Press; 1995.
44. Wise RA, Bozarth MA. Brain substrates for reinforcement and drug-self-administration. Prog Neuropsychopharmacol. 1981;5:467-474.
45. Volkow ND, Fowler JS, Wolf AP, Hitzemann R, Dewey S, Bendriem B, Alpert R, Hoff, A. Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am J Psychiatry. 1991;148(5):621-626.
46. London ED, Cascella NG, Wong DF, Phillips, RL, Dannals RF, Links JM, Herning R, Grayson R, Jaffe JH, Wagner HN Jr. Cocaine- induced reduction of glucose utilization in human brain. A study of positron emission tomography and [fluorine 18]- fluorodeoxyglucose. Arch Gen Psychiatry. 1990;47:567-574.
47. Weiss F. Neurochemical adaptation in brain reward systems during drug addiction. In: Advancing Understanding of Drug Addiction. Washington, DC: National Academy Press; 1996.
48. Kreek MJ, Koob GF. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 1998;51(1-2):23-48.
49. Self DW, Nestler EJ. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend 1998;51(1-2):49-60.
50. Roberts DCS, Corcoran ME, Fibiger HC. On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine. Pharmacol Biochem Behavior. 1977;6:615-620.
51. Phillips AG, Pfaus JG, Blaha CD. Dopamine and motivated behavior: insights provided by in vivo analyses. In: Willner P, Scheel-Kruger J, eds. The Mesolimbic Dopamine System: From Motivation to Action. New York: John Wiley & Sons; 1995.
52. Volkow ND. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature. 1997;386(6227):827-830.
53. Volkow ND, Fowler JS, Wang G, Hitzemann R, Logan J, Schyler DJ, Dewey SL, Wolf AP. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse. 1993:14:169-177.
54. Volkow ND, Hitzemann R, Wang GJ, Fowler JS, Wolf AP, Handelsman L Long-term frontal brain metabolic changes in cocaine abusers. Synapse. 1992;11:184-190.
55. Childress AR, McLellan AT, Ehrman R, O'Brien CP. Classically conditioned responses in opioid and cocaine dependence: a role in relapse? In: Ray B, ed. Learning Factors in SubstanceAbuse. Rockville, Md.: National Institute on Drug Abuse; 1998. Research Monograph 84.
56. Baxter LR, Schwartz JM, Phelps M, et al. Localization of neurochemical effects of cocaine and other stimulants in the human brain. J Clin Psychiatry. 1988;49:23-26.
57. Volkow ND, Mullani N, Gould KL, Adler S, Krajewski K. Cerebral blood flow in chronic cocaine users: a study with positron emission tomography. Br J Psychiatry. 1988; 152:641-648
58. Holman BL, Mendelson J, Garada B, Teoh SK, Hallgring E, Johnson KA, Mello NK. Regional cerebral blood flow improves with treatment in chronic cocaine polydrug users. J Nucl Med. 1993;34:723-727.
59. Pearlson GD, Jeffery PJ, Harris GJ, Ross CA, Fischman MW, Camargo EE. Correlation of acute cocaine-induced changes in local cerebral blood flow with subjective effects. Am J Psychiatry. 1993;150(3):495-497.
60. O'Brien CP. Experimental analysis of conditioning factors in human narcotic addiction. Pharmacol Rev. 1975;27(4):533-543.
61. Childress AR, McElgin W, Mozley PD, Fitzgerald J, Reivich M, O'Brien CP. Iimbic activation during cue-induced cocaine craving. Am J Psychiatry. 1999; 156:11-18.
62. Stewart RG, Ware LG. The Medical Outcomes Study. Santa Monica, Calif.: Rand Corporation Press; 1989.
63. McLellan AT, Woody GE, Metzger D, McKay J, Alterman AI, O'Brien CP. Evaluating the effectiveness of treatments for substance use disorders: Reasonable expectations, appropriate comparisons. Milbank Q. 1996;74(1): 51-85.
64. Ball JC, RossA. The Effectiveness of Methadone Maintenance Treatment. New York: Springer-Verlag; 1991.
65. Food and Drug Administration. Compliance Policy Guidelines. Code of Federal Regulations. Vol 21, paragraph 310. Washington, DC: Government Printing Office; 1990.
66. Metzger DS, Woody GE, McLellan AT, Druley P, DePhillipis D, O'Brien C, Stolley P, Abrutyn E. HIV seroconversion among in and out of treatment intravenous drug users: an 18-month prospective follow-up. AIDS. 1993;6(9):1049-1056.
67. Neaiguus A, Sufian M., Friedman SR. Effects of outreach intervention on risk reduction among intravenous drug users. AIDS. 1990;2:253-271.
68. Booth R, Weibel WW. Effectiveness of reducing needle-related risk behaviors for HIV through indigenous outreach to injection drug users. Am J Addict. 1992;23:277-287.
69. Anderson MD, Smereck GA, Braunstein MS. LIGHT model: an effective intervention to change high-risk AIDS behavior among hard-to-reach urban drug users. Am J Drug Alcohol Abuse. 1993;19:309-325.
70. McLellan AT, Metzger DS, Alterman AI, Woody GE, Durell J, O'Brien CP. Is addiction treatment –worth it—? Public health expectations, policy-based comparisons. In: Lewis DL, ed. Proceedings of the Josiah Macy Conference on Medical Education. New York: Josiah Macy Foundation; 1995;165-212.
71. Booth RE, Crowley TJ, Zhang Y. Substance abuse treatment entry, retention and effectiveness: out-of-treatment opiate injection drug users. Drug Alcohol Depend 1996;42,11-20.
72. Strecher VJ, Korbin SC, Kreuter MW, Roodhouse K, Farrel D. Opportunities for alcohol screening and counseling in primary care. J Fam Pract 1994;39:26-32.
73. Babor TF, Ritson EB,. Hodgson RJ. Alcohol-related problems in the primary care setting: a review of early intervention strategies. Br J Addict. 1986;81:23-46.
74. Svikis DS, Golden AS, Huggins GR, Pickens RW, McCaul ME, et al. Cost-effectiveness of treatment for drug-abusing pregnant women. Drug Alcohol Depend. 1997;45(l,2):105-115.
75. Finnegan L, Kandall S. Maternal and neonatal effects of alcohol and drugs. In: Lowinson J, et al., eds. Substance Abuse: A Comprehensive Textbook. 2nd ed. Philadelphia: Williams and Wilkins; 1992.
76. Glantz JK, Woods JR. Cocaine, heroin and phyencyclidine: obstetric perspectives. Clin Obstet Gynecol. 1993;85:468-479.
77. Haller DL, Knisely JS, Dawson KS, Schnoll SH. Perinatal substance abusers: psychological and psychosocial characteristics. J Nerv Ment Dis. 1993; 18:509-513.
78. Philbbs CS, Batema DA, Schwartz RM. The neonatal costs of maternal cocaine use. JAMA 1991;11:1521-1526.
79. Anton RE New directions in the pharmacotherapy of alcoholism. Psychiatric Ann. 1995;25:353-362.
80. O'Brien CP. Recent developments in the pharmacotherapy of substance abuse. J Consult Clin Psychol 1996;664:677-686.
81. Nightingale SL. Levomethadyl approved for the treatment of opiate dependence. JAMA 1993;270:1290.
82. Milby JB. Methadone maintenance to abstinence. How many make it? J Nerv Ment Dis. 1998;176;409-422.
83. Gossop M, Johns A, Green L. Opiate withdrawal: inpatient versus outpatient programmes and preferred versus random assignment. Br Med J. 1986;293:103-104.
84. Mattick RP, Hall W. Are detoxification programmes effective? Lancet. 1996;347:97-100.
85. National Consensus Development Panel. Effective Medical Treatment of Opiate Addiction: Report of the NIH Consensus Conference on the Treatment of Opiate Addiction. JAMA. 1998;280(22):1936-1943.
86. Bickel WK, Amass L. Buprenorphine treatment of opioid dependence: a review. Exp Clin Psychopharmacol. 1995; 3:477-489.
87. Johnson, RE, Cone EJ, Henningfield JE, Fudala PJ. Use of buprenorphine in the treatment of opioid addiction. Clinical Pharmacol Ther. 1989;46:335-343.
88. O'Brien CP, Childress AR, McLellan AT, Ternes J, Ehrman R. Use of naltrexone to extinguish opioid conditioned responses. J Clin Psychiatry. 1984;45(9):53-56.
89. Resnick RB, Volavka J, Freedman AM, Thomas M. Studies of EN-1639-A (naltrexone): a new narcotic antagonist. Am J Psychiatry. 1974;131:646-650.
90. O'Brien CP, Greenstein RA, Mintz J, Woody GE. Clinical experience with naltrexone. Am J Drug Alcohol Abuse. 1975; 2:365-377.
91. Martin, WR, Jasinski DR, Mansky PA. Naltrexone, an antagonist for the treatment of heroin dependence. Arch Gen Psychiatry. 1973;28:784-791.
92. Ling W, Wesson DR. Naltrexone treatment for addicted health care professionals: a collaborative private practice experience. J Clin Psychiatry. 1984;5(9):46-48.
93. Cornish J, Metzger D, Woody G, et al. Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat. 1998; 13:477-489.
94. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
95. O'Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49:881-887.
96. Sass H, Soyka M, Mann K, Zieglgasberger W. Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53:673-680.
97. Fox BS. Development of a therapeutic vaccine for the treatment of cocaine addiction. Drug Alcohol Depend. 1997; 48:153-158.
98. Woody GE, O'Brien CP, Rickels K. Depression and anxiety in heroin addicts: a placebo-controlled study of doxepin in combination with methadone. Am J Psychiatry. 1975; 132:447-450.
99. Carroll, KM, Rounsaville BJ, Gordon LT, Nich C, Jatlow P, Bisighini RM, Gawin FH. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch Gen Psychiatry. 1994;51:177-187.
100. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA 1996; 275:761-767.
101. Kosten TR, Rounsaville BJ, Kleber HD. Multidimensionality and prediction and treatment outcome in opioid addicts: 2.5- year follow-up. Compr Psychiatry. 1987;28:3-13.
102. Rounsaville BJ, Dolinsky ZS, Babor TF, Meyer RE. Psychopathology as a predictor of treatment outcome in alcoholics. Arch Gen Psychiatry. 1987;44:505-513.
103. Carroll KM, Power MD, Bryant K, Rounsaville BJ. One-year follow-up status of treatment-seeking cocaine abusers: psychopathology and dependence severity as predictors of outcome. J Nerv Ment Dis. 1993; 181:71-79.
104. Babor TF. Brief intervention strategies for harmful drinkers: new directions for medical education. Can Med Assoc J. 1990;143:1070-1076.
105. Healther N, Campion PD, Neville RG, McCabe D. Evaluation of a controlled drinking minimal intervention for problem drinkers in general practice. Gen Pract. 1987;37:358-363.
106. Miller WR. Techniques to modify hazardous drinking patterns. Recent Dev Alcohol. 1987;5:425-438.
107. Kristenson H, Ohlin H, Hulten-Nosslin M, Trell E, Hood B. Identification and intervention of heavy drinking in middleaged men. Alcohol Clin Exp Res. 1983;7:203-209.
108. Wallace P, Cutler S, Haines A. Randomized controlled trial of general practitioner intervention in patients with excessive alcohol consumption. Br Med J. 1988;297:663-668.
109. World Health Organization Brief Intervention Study Group. A cross-national trial of brief intervention with heavy drinkers. Am J Public Health. 1996;86:948-955.
110. Fleming MF, Barry KL, Manwell LB, Johnson K, London R. Brief physician advice for problem alcohol drinkers: a randomized controlled trial in community-based primary care practices. JAMA 1997;277:1039-1045.
111. Bien, TH, Miller WR, Tonigan JS. Brief interventions for alcohol problems: a review. Addiction. 1993;88:315-335.
112. Fleming MF, Mundt MP, French MT, Manwell LB, Stafffacher EA, Barry LB. Benefit-cost analyses of brief physician advice with problem drinkers in primary care settings. Med Care. 2000;38:7-18.
113. Moos RH, Finney JW, Cronkite RC. Alcoholism Treatment- Context, Process and Outcome. New York: Oxford University Press; 1990.
114. Simpson D, Savage L Drug abuse treatment readmissions and outcomes. Arch Gen Psychiatry. 1980;37:896-901.
115. Hubbard RL, Marsden ME, Rachal JV, Harwood HJ, Cavanaugh ER, Ginzburg HM. Drug Abuse Treatments National Study of Effectiveness. Chapel Hill, NC: University of North Carolina Press; 1989.
116. DeLeon G. The Therapeutic Community: Study of Effectiveness Treatment Rockville, Md.: National Institute on Drug Abuse; 1984. NIDA Research Monograph 84-1286.
117. Miller WR, Hester RK. The effectiveness of alcoholism treatment methods: what research reveals. In: Miller WR, Heather N, eds. Treating Addictive Behaviors: Process of Change. New York: Plenum Press; 1986.
118. Gerstein D, Harwood H, eds. Treating Drug Problems. Vol 1. Washington, DC: National Academy Press; 1990.
119. Gerstein D, Judd LL, Rovner SA. Career dynamics of female heroin addicts. Am J Drug Alcohol Abase. 1979; 6(1):1-23.
120. McLellan AT, Alterman AI, Metzger D S, Grissom G, Woody GE, Luborsky L, O'Brien CP. Similarity of outcome predictors across opiate, cocaine and alcohol treatments: role of treatment services. J Clin Consult Psychol. 1991; 62(6): 1141-1158.
121. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry. 1997;54(8):737-742.
122. McLellan AT, Woody GE, Metzger D, McKay J, Alterman AI, O'Brien CP. Evaluating the effectiveness of treatments for substance use disorders: reasonable expectations, appropriate comparisons. Milbank Q 1996;74(1):51-85.
123. O'Brien CP, McLellan AT. Myths about the treatment of addiction. Lancet 1996;347:237-240.
124. Graber AL, Davidson P, Brown A, McRae J, Woolridge K. Dropout and relapse during diabetes care. Diabetes Care. 1992;15(11):477-1483.
125. Horowitz RI. Treatment adherence and risk of death after a myocardial heart infarction. Lancet 1993;336(8714):542-545.
126. Dekker FW, Dieleman FE, Kaptein AA, Mulder JD. Compliance with pulmonary medication in general practice. EurRespir J. 1993;6(6):886-890.
127. Clark LT. Improving compliance and increasing control of hypertension: needs of special hypertensive populations. Am Heart J. 1991;121(2, pt2):664-669.
128. Kurtz SM. Adherence to diabetic regimes: Empirical status and clinical applications. Diabetes Educ. 1990;16(1):50-59.
129. Sinnock P. Hospitalization of diabetes. In: Diabetes Data. National Diabetes Data Group. Bethesda, Md.: National Institutes of Health; 1985.
130. Herman WH, Teutsch SM. Diabetic renal disorders. In: Diabetes Data. National Diabetes Data Group. Bethesda, Md.: National Institutes of Health; 1985.
131. Schaub AF, Steiner A, Vetter W. Compliance to treatment. J Clin Exp Hypertens. 1983;15(6):1121-1130.
132. Gorlin R. Hypertension and ischemic heart disease: the challenge of the 1990s. Am Heart J. 1991:121(2, pt 2):658-663.
133. Satel SL, Price LH, Palumbo JM, McDougle CJ, et al. Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study. Am J Psychiatry. 1991;148:1712-1716.
134. Weddington WW. Cocaine abstinence: –withdrawal— or residua of chronic intoxication? Am J Psychiatry. 1992;149:1761-1762.
135. Gawin FH, Kleber HD. Abstinence symptomatology and psychiatric diagnoses in cocaine abusers. Arch Gen Psychiatry. 1986;43:107-113.
136. Gawin FH, Ellinwood EH. Cocaine and other stimulants: actions, abuse, and treatment. N Engl J Med 1988:318:1173-1182.
137. Fleming MF, Barry KL, eds. Addictive Disorders. St. Louis, Mo.: Mosby Yearbook; 1992.
138. Hayashida M, Alterman AI, McLellan AT, et al. Comparative effectiveness of inpatient and outpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome. N Engl J Med. 1989:320:358-365.
139. Stockwell T, Bolt L, Milner I, Puch P, Young I. Home detoxification for problem drinkers: acceptability to clients, relatives, general practioners and outcome after 60 days. Br J Addict. 1990;85:61-70.
140. Elman I, D'Ambra MN, Krause S, Beiter H, Kane M, Morris R, Tuffy L, Gastfriend DR. Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones, and clinical outcomes. Drug Alcohol Depend. 2001;61(2): 163-173.
141. Brewer C, Williams J, Carreno-Rendueles E, Bobes-Garcia J. Unethical promotion of rapid opiate detoxification under anaestehsia (RODA). Lancet. 2001;351(9097):218.
142. Cushman P, Dole VP. Detoxification of rehabilitated methadone- maintained patients. JAMA. 1973;226:747-752.
143. Institute of Medicine. Federal Regulation of Methadone Treatment. Washington, DC: National Academy Press; 1995
144. Gossop M, Johns A, Green L. Opiate withdrawal: inpatient versus outpatient programmes and preferred versus random assignment Br Med J. 1986;293:103-104.
145. Lipton DS, Maranda MJ. Detoxification from heroin dependency: an overview of method and effectiveness. Adv Alcohol Subst Abuse. 1983;2:31-55.
146. Alterman A, McKay J, Mulvaney F, McLellan AT. Prediction of attrition from day hospital treatment in lower socioeconomic cocaine-dependent men. Drug Alcohol Depend. 1996;40:227-233.
147. Kang SY, Kleinman PH, Woody GE, Millman RB, et al. Outcomes for cocaine abusers after once-a-week psychosocial therapy. Am J Psychiatry. 1991; 148:630-635.
148. Carroll KM, Rounsaville BJ, Gawin FH. A comparative trial of psychotherapies for ambulatory cocaine abusers: relapse prevention and interpersonal psychotherapy. Am J Drug Alcohol Abuse. 1991;17:229-247.
149. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
150. O'Malley SS, Jaffe AJ, Rode S, Rounsaville BJ. Experience of a –slip— among alcoholics treated with naltrexone or placebo. Am J Psychiatry. 1996; 153:281-283.
151. McLellan AT, Ball JC. Is methadone treatment effective? In: Rettig R, ed. A Re- Evaluation of Federal Regulations on Methadone Treatment Washington, DC: National Academy Press; 1995.
152. McLellan AT, Woody GE, Metzger D, McKay J, Alterman AI, O'Brien CP. Evaluating the effectiveness of treatments for substance use disorders: reasonable expectations, appropriate comparisons. In: Fox D, ed. The Milbank Foundation Volume on Health Policy Issues. New York: Milbank Foundation Press; 1995.
153. McLellan AT, Weisner C. Achieving the public health potential of substance abuse treatment: implications for patient referral, treatment –matching— and outcome evaluation. In: Bickel W, DeGrandpre R, eds. Drug Policy and Human Nature. Philadelphia: Willliams & Wilkins; 1996.
154. McLellan AT, Durell J. Evaluating substance abuse and psychiatric treatments: conceptual and methodological considerations. In: Sederer L, ed. Outcomes Assessment in Clinical Practice. New York: Williams & Wilkins; 1995.
155. McCrady BS, Noel NE, Abrams DB, Stout RL, Nelson HF, Hay WM. Comparative effectiveness of three types of spouse involvement in outpatient behavioral alcoholism treatment. J Stud Alcohol. 1986(a);47:459-467.
156. Alterman AI, McLellan AT, O'Brien CP, August DS, Snider EC, Cornish JC, Droba M, Hall CP, Raphaelson A, Schrade F. Effectiveness and costs of inpatient versus day hospital cocaine rehabilitation. J Nerv Ment Dis. 1994;182:157-163.
157. Miller WR, Hester RK. Inpatient alcoholism treatment: who benefits? Am Psychol. 1986;41:794-805.
158. Holder HD, Longabaugh R, Miller WR, Rubonis A. The cost effectiveness of treatment for alcohol problems: a first approximation. J Stud Alcohol. 1991;52:517-540.
159. Walsh DC, Hingson R, Merrigan D, et al. A randomized trial of treatment options for alcohol-abusing workers. N Engl J Med. 1991;325:775-782.
160. Finney JW, Halm AC, Moos RH. The effectiveness of inpatient and outpatient treatment of substance abuse: the need to focus on mediators and moderators of setting effects. Addiction. 1996;91:1773-1796.
161. McKay JR, Alterman AI, McLellan AT, Snider C, et al. Treatment goals, continuity of care, and outcome in a day hospital substance abuse rehabilitation program. Am J Psychiatry. 1994; 151:254-259.
162. McKay JR, McLellan AT, Alterman AI. An evaluation of the Cleveland Criteria for Inpatient Treatment of Substance Abuse. Am J Psychiatry. 1992;149:1212-1218.
163. Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York: Springer-Verlag; 1991.
164. DeLeon G. The Therapeutic Community: Study of Effectiveness Treatment Research. Rockville, Md.: National Institute on Drug Abuse; 1984. NIDA Monograph 84-1286.
165. Hubbard RL, Marsden ME, Rachal JV, Harwood HJ, Cavanaugh ER, Ginzburg HM. Drug Abuse Treatment: A National Study of Effectiveness. Chapel Hill, NC: University of North Carolina Press; 1989.
166. Simpson DD. Treatment for drug abuse: follow-up outcomes and length of time spent. Arch Gen Psychiatry. 1981;38:875-880.
167. Simpson DD, Joe GW, Brown BS. Treatment retention and follow- up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addictive Behav. 1997;11(4):294-301.
168. Project MATCH Research Group. Matching alcoholism treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol. 1997;58:7-29.
169. McLatchie BH, Lomp KG. Alcoholics Anonymous affiliation and treatment outcome among a clinical sample of problem drinkers. Am J Drug Alcohol Abuse. 1988;14:309-324.
170. McKay JR, Alterman AI, Cacciola JS, Rutherford MR, O'Brien CP, Koppenhaver J. Group counseling vs. individualized relapse prevention aftercare following intensive outpatient treatment for cocaine dependence: initial results. J Consult Clin Psychol 1997;65:778-788.
171. Timko C, Moos RH, Finney JW, Moos BS. Outcome of treatment for alcohol abuse and involvement in Alcoholics Anonymous among previously untreated problem drinkers. J Ment Health Admin 1994;21:145-160.
172. Tonigan JS, Toscova R, Miller WR. Meta-analysis of the literature on Alcoholics Anonymous: sample and study characteristics moderate findings. J Stud Alcohol. 1996;57:65-72.
173. Morgenstern J, Labouvie E, McCrady B, Kahler C, Frey R. Affiliation with Alcoholics Anonymous following treatment: A study of its therapeutic effects and mechanisms of action. J Consult Clin Psychol. 2001;167:85-92.
174. McLellan AT, Arndt IO, Woody GE, Metzger D. Psychosocial services in substance abuse treatment? A dose-ranging study of psychosocial services. JAMA. 1993; 269(15):1953-1959.
175. Florentine R, Anglin MD. Does increasing the opportunity for counseling increase the effectiveness of outpatient drug treatment? Am J Drug Alcohol Abuse. 1997;23(3):369-382.
176. Luborsky L, McLellan AT, Woody GE, O'Brien CP. Therapist success and its determinants. Arch Gen Psychiatry. 1985;42:602-611.
177. McLellan AT, Woody GE, Luborsky L, Goehl L. Is the counselor an –active ingredient— in substance abuse rehabilitation? J Nerv Ment Dis. 1988; 176:423-430.
178. Miller WR, Taylor CA, West JC. Focused versus broad-spectrum behavior therapy for problem drinkers. J Consult Clin Psychol 1980;48:590-601.
179. McCaul M, Svikis D. Improving Client Compliance in Outpatient Treatment: Counselor-Targeted linterventions. Rockville, Md.: National Institute on Drug Abuse; 1991. NIDA Research Monograph 106.
180. Miller WR, Benefield RG, Tonigan JS. Enhancing motivation for change in problem drinking: a controlled comparison of two therapist styles. J Consult Clin Psychol. 1993;61:455-461.
181. Najavits LM, Weiss RD. Variations in therapist effectiveness in the treatment of patients with substance use disorders: An empirical review. Addiction. 1994;89(6):679-688.
182. Valle S. Interpersonal functioning of alcoholism counselors and treatment outcome. J Stud Alcohol. 1981;42:783-790.
183. Azrin NH, Sisson RW, Meyers RW, Godley M. Alcoholism treatment by disulfiram and community reinforcement therapy. J Behav Ther Exp Psychiatry. 1982;13:105-112.
184. Meyers RJ, Smith JE. Clinical Guide to Alcohol Treatment: The Community Reinforcement Approach. New York: Guilford; 1995.
185. Higgins ST, Budney AJ, Bickel WK, Badger GJ, Foerg FE, Ogden D. Outpatient behavioral treatment for cocaine dependence: one-year outcome. Exp Clin PsychopharmacoL 1995;3:205-212.
186. Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badger GJ. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry. 1994;51:568-576.
187. Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg FE, Badger GJ. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry. 1993; 150:763-769.
188. Higgins ST, Delaney DD, Budney AJ, Bickel WK, Hughes JR, Foerg F, Fenwick JW. A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry. 1991; 148:1218-1224.
189. Gastfriend D, McLellan AT. Treatment matching: theoretical basis and practical implications. In: Samet J, Stein M, eds. Med Clin North Am. New York: WB Saunders; 1997.
190. McLellan AT, Grissom G, Zanis D, Bril P. Problem-service –matching— in addiction treatment: a prospective study in four programs. Arch Gen Psychiatry. 1997;54:730-735.
191. Cornelius IR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, Thase JE, Black A. Fluoxetine in depressed alcoholics: a double-blind, placebo controlled trial. Arch Gen Psychiatry. 1997;54:700-705.
192. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA. 1996;275:761-767.
193. McGrath PJ, Nunes EV, Stewart JW, Goldman D, Agosti V, Ocepek-Welikson K, Quitkin FM. Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry. 1996;53:232-240.
194. Kranzler HR, Burleson JA, Del Boca FK, Babor TF, Korner P, Brown J, Bohn, MJ. Buspirone treatment of anxious alcoholics: a placebo-controlled trial. Arch Gen Psychiatry. 1994;517:20-731.
195. Carroll KM, Nich C, Rounsaville BJ. Differential symptom reduction in depressed cocaine abusers treated with psychotherapy and pharmacotherapy. J Nerv Ment Dis. 1995; 183:251-259.
196. Woody GE, McLellan AT, Luborsky L, et al. Psychiatric severity as a predictor of benefits from psychotherapy. Am J Psychiatry. 1984;141:1171-1177.
197. Belenko S. Behind Bars: Substance Abuse and America's Prison Population. New York: National Center for Addiction and Substance Abuse at Columbia University; 1998.
198. Inciardi JA. Some considerations on the clinical efficacy of compulsory treatment: reviewing the New York experience. In: Leukefeld CG, Tims MF, eds. Compulsory Treatment of Drug Abuse: Research and Clinical Practice. Rockville, Md.: National Institute on Drug Abuse; 1988. NIDA Research Monograph 86.